Thursday, April 11, 2019

International Research Ethics Education and Curriculum Development Award (PAR-19-244)

Funding Opportunity Announcement (FOA) Number PAR-19-244

The over-arching goal of this R25 program is to support educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications.
  • Courses for Skills Development
  • Mentoring Activities
  • Curriculum or Methods Development
The goal of this initiative is to support educational activities that foster a better understanding of the ethics of international biomedical, behavioral and clinical research and enhance the application of research ethics principles in low- and middle-income countries (LMICs). This program aims to increase the number of LMIC research intensive institutions that can provide advanced education in international research ethics. 

Eligibility

Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply

Applications may be submitted by U.S., HIC or LMIC research intensive institutions, however, all applications from U.S. or other HIC institutions must include a collaborating institution from a LMIC (defined by the World Bank classification system- also refer to NOT-TW-12-011"Notice of Change in Country Eligibility for Fogarty International Training Grants", for additional information)

Key Dates


Open Date (Earliest Submission Date) 
May 04, 2019

Letter of Intent Due Date(s)
30 days before application due date.

Application Due Date(s)
June 4, 2019

Award

Funding Instrument
Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.

Award Budget
Applications may request up to $230,000 direct costs per year..

Award Project Period
The total project period may not exceed 5 years.


Posted by at

Thursday, April 4, 2019

*UPDATED* NIH-NSF Ecology and Evolution of Infectious Diseases Initiative (EEID) (NSF-19-592)

Status: Accepting applications
Apply through NSF program solicitation

Announcement(s)

From the National Science Foundation (NSF):
Related NIH Notice:
Deadlines
  • Upcoming application deadline: November 20, 2019
  • Estimated future deadlines: third Wednesday in November, annually

Eligibility information

Who May Submit Proposals: Institutions of Higher Education (IHEs) and Foreign Organizations.
Who May Serve as PI: There are no restrictions or limits.
Limit on Number of Proposals per Organization: There are no restrictions or limits.

 Award information

Anticipated Type of Award: Standard Grant or Continuing Grant
Estimated Number of Awards: 8
Anticipated Funding Amount: $20,000,000

Program Overview

This joint National Institutes of Health (NIH) - National Science Foundation (NSF) initiative supports efforts to understand the underlying ecological and biological mechanisms that govern relationships between human-induced environmental changes and the emergence and transmission of infectious diseases. The highly interdisciplinary research projects funded under this program apply both ecological and biomedical methods, and study how environmental events such as habitat alteration, biological invasion, climate change, and pollution alter the risks of emergence and transmission of viral, parasitic, and bacterial diseases in humans and other animals. Projects are encouraged to consider how integrated environmental and biomedical approaches to infectious diseases may enhance our ability to predict and control them.
Posted by at

Global Infectious Disease Research Training Program (D43 Clinical Trial Optional) (PAR-18-840)

Status: Accepting applications

Announcement(s)

Deadlines

  • ​Letter of intent due dates: 30 days prior to the application due date
  • Upcoming application due dates: July 25, 2019

Eligibility


Eligibility: Global Infectious Disease Research Training Program (D43)
  • U.S. Institutions with a demonstrated collaboration with a researcher in low- and middle-income country (LMIC) institutions may apply.
  • Foreign institutions in LMICs may also apply.
  • Applicant institution must have robust and high-quality research ongoing in the area(s) proposed.
Eligibility: Planning Grant for Global Infectious Disease Research Training Program (D71)
  • Applicants may only be submitted by foreign institutions in LMICs, as defined by the World Bank Classification system .
  • Foreign applicants should apply in collaboration with U.S. institutions and must name an individual in the proposed institution as the major collaborator.
Applicant institutions for both the full institutional grant and the planning grant may submit more than one application, provided that each application is scientifically distinct.

Program Overview

The Global Infectious Disease (GID) program addresses research training needs related to infectious diseases that are predominantly endemic in or impact upon people living in developing countries. The training programs include a variety of research training options to match the needs of the developing country institution. The ultimate goal is to build a critical mass of researchers and support staff to conduct independent infectious disease research in developing country institutions.

Posted by at

Monday, March 4, 2019

The e-ASIA JRP 8th Call for Research Proposals on the topic of “Infectious Diseases, Antimicrobial and Multidrug Resistance”

Call for Research Proposals 2019
Deadline for submission: 14 May 2019


The e-ASIA Joint Research Program (e-ASIA JRP) is a collaborative funding program from ASEAN member countries and Japan, Korea, U.S., Russia, New Zealand, Australia created to support the multinational research projects contributing to the development of future technology.

 Participating Member Organizations (listed in alphabetical order):
1) Cambodia: Ministry of Health (MOH)
2) Indonesia: Ministry of Research, Technology and Higher Education (RISTEKDIKTI)
3) Japan: Japan Agency for Medical Research and Development (AMED)
4) Myanmar: Ministry of Education (MOE)
5) New Zealand: Health Research Council (HRC)
6) Philippines: Department of Science and Technology (DOST-PCHRD)
7) Russia: Russian Foundation for Basic Research (RFBR)
8) Thailand: National Science and Technology Development Agency (NSTDA)
9) USA: National Institute of Allergy and Infectious Diseases (NIAID)
10) USA: National Cancer Institute (NCI)

A project consortium must be consisted of at least three eligible research teams from at least three different participating countries listed above. Each research team shall be led by a Principal Investigator (PI), and a consortium shall be led by a Lead Principal Investigator (Lead PI) specified among the PIs. 


Thailand: National Science and Technology Development Agency (NSTDA) 
I. Eligibility for Thai applicants The applicants must be researchers and/or university professors/instructors who work in public research institute or university in Thailand, and are competent in conducting a research with international partners.

"NSTDA will provide support only for Infectious Diseases and AMR while cancer research will be supported by TCELS".

II. Support   The total budget for the Thai researcher over a full 3-year period is up to                   5, 000,000 THB. The budget for a project may differ each year, depending on the content of activities.

III. Evaluation of Project Proposals Proposals will be peer-reviewed, and evaluated by a committee. The final selection will be done by the international selection committee of e-ASIA.

III.I Evaluation Criteria To be funded, proposals must be internationally competitive. It should lead to the advancement of the research field, or novel applications or increased of research capacity.

Key evaluation criteria are:

 Significance and impact of the research
 Scientific Rationale: novelty, importance and timeliness of the research
 Design and feasibility of the project plan
 Partnership: including strength and clarity of collaborations and opportunities provided, quality of the project management structure proposed;
 Quality and suitability of the research environment and of the facilities;

 Ethical considerations and governance arrangements

Deadline: 
17:00 (Thai Standard Time, UTC+7) 14th May 2019


Contact Information
Thailand:

Ms. Jirawadee Matoon
International Relation Officer, International Collaboration
National Science and Technology Development Agency
111 Thailand Science Park
Klong Luang, Pathumthani 12120

Tel.  +662 117 6932
email: jirawadee.matoon@nstda.or.th

Secretariat
Mr. Yoshihide Kobayashi
e-ASIA JRP Secretariat / Japan Science and Technology Agency

Room 218 Innovation Cluster1 Building
National Science and Technology Development Agency (NSTDA)
111 Thailand Science Park, Phahonyothin Road
Khlong Nueng, Khlong Luang, Pathum Thani 12120 THAILAND
Tel: +66-2-564-7713   H/P: +66-61-421-0316

E-mail: easia_secretariat@jst.go.jp

Website: http://www.the-easia.org/jrp/index.html
Posted by at

Wednesday, February 27, 2019

Neglected Tropical Diseases Data Innovation Incubator (BMGF)

The Neglected Tropical Diseases (NTD) team at the Bill & Melinda Gates Foundation supports global efforts to control, eliminate, and eradicate NTDs. The team focuses on seven of the ten London Declaration diseases, as well as on cross-cutting efforts to improve the quality and impact of NTD programs through a variety of levers, including data systems. Strengthening NTD data systems and ensuring use of quality data for programmatic decision-making at the country, regional, and global levels are priority components of these cross-cutting efforts.

National NTD programs rely on timely and quality data to make decisions throughout the duration of the program. The quality of these data ultimately depends on the systems, tools, and processes at the points-of-collection, collation, and analysis at sub-national and national levels. Many of the current data-related tools and approaches used by NTD programs are sub-optimal and hinder the ability of the national program to deliver. Specifically, a limited NTD data system can lead to an inaccurate understanding of program performance and reduced likelihood of achieving control and elimination goals. Moreover, poor quality country data and data systems introduces delay and inaccuracies in regional and global reporting, drug forecasting, and inefficient allocation of resources.

This Grand Challenge seeks innovative ideas for how to improve the quality, completeness, and timeliness of routine NTD data and ensure programmatic decision-making is based on the best available data. Such outcomes will help target interventions to all at-risk populations and achieve high intervention coverage and maximal impact on infection and morbidity.

Eligibility
Grand Challenges is open to both foreign and domestic organizations, including non-profit organizations, for- profit companies, international organizations, government agencies and academic institutions.

Award Budget
For Round 1, we are suggesting a maximum budget of $200,000 USD for up to 6 months of work. For Round 2, we have decided not to specify funding limits or expectations. The number of awards and quantity of each award amount will depend upon the quality of the proposals received.
Proposers are expected to develop a budget commensurate with the scope and scale of the work
necessary to achieve their detailed objectives; however, the objectives should be achievable within 12-18 months from onset of Round 2 funding.

Award Project Period
The Incubator funding will be structured in two rounds. Round 1 funding will support proof-of-concept testing of the proposed solution over 3 to 6 months. After this initial stage, we then expect to invite a subset of the most successful Round 1 grantees to apply for Round 2 funding to test their solutions more broadly over 12-18 months. As results from Round 2 would ultimately inform country scale-up, your proposal should identify the necessary conditions for its success

Deadline
Application Due Date: The application deadline for this RFP is March 25, 2019, at 11:30 a.m. U.S. Pacific Daylight Time, after which time applications will no longer be accepted.

Inquiries
Please direct all questions about this initiative, selection criteria or application instructions by e-mail to the following address: grandchallenges@gatesfoundation.org.

Full Details and Supporting Materials:

https://gcgh.grandchallenges.org/challenge/neglected-tropical-diseases-data-innovation-incubator
Posted by at

Friday, January 18, 2019

MMV 17th Call for proposals Drug Discovery Projects

17th Call for Proposals
Drug Discovery Projects

 All applications for any of the below must use the specified templates and should be sent electronically to proposals@mmv.org by 10.00 AM (Bangkok time) Friday, 29 March 2019.

 Medicines for Malaria Venture (MMV) welcomes proposals in the following three areas:


 1. Compounds addressing the key priorities of the malaria eradication agenda

 Novel families of molecules in the hit-to-lead or lead optimization stages are sought without G6PD deficiency liabilities that either:

 kill or reactivate hypnozoites for use as part of a P. vivax radical cure; or  
have activity against sexual stage V gametocytes and evidence of transmission blocking in SMFA.

 2. Compounds having activity against asexual liver and/or blood stages

 Novel chemical series with EC50<500nM and which have one or more of the following key features:

 A known, novel mechanism of action;
An inability to select resistant mutants in vitro;
Activity at more than one life-cycle stage;
A long half-life (ideally >4h in rodents) and confirmed in vivo efficacy.
For advanced series, we are seeking novel compounds with, ideally, a predicted human half-life >100h and a predicted oral single human dose <500mg or an i.m. dose that can be administered in <1mL and sufficient for up to 3 months’ protection in humans.

 3. Novel approaches for screening

 To help identify new phenotypic and/ or target based hits, as well as confirm activity of MMV compounds on all human malaria asexual blood stages, new screening proposals are sought amongst the three categories below:

 Validated Plasmodium target-based assays, ideally with evidence of target essentiality beyond asexual blood stages.  Biological validation should be supported by a biological target based screening assay suited for identification of novel chemical series. 
Novel whole cell phenotypic screening paradigms to potentially identify new relevant chemistry.
Asexual blood stage assays for vivax and ovale malaria.
Please complete the 3-page Letter of Interest template.. Proposals involving a biological target should also include the target information template. See further instructions  on how to complete the LOI.
Compounds for Target Identification
MMV also welcomes requests for support to investigate the mechanism of action of compounds:

 MMV is a founder member of the Malaria Drug Accelerator (MalDA).  MalDA, a consortium funded by the Bill and Melinda Gates Foundation and led by Prof. Elizabeth Winzeler (UCSD), is working on a project to identify mechanisms of action of antimalarial compounds having phenotypic activity.  Compounds can be considered for such target identification activities provided that the following criteria are met:

  • The Plasmodium whole cell EC50 <1uM and the chemical structure can be shared
  • A minimum of 10mgs of compound can be provided to the consortium

A one page Excel template needs to be completed to submit a compound for target ID.

 Full announcement- https://www.mmv.org/research-development/information-scientists/call-proposals/17th-call-proposals 
Posted by at

Thursday, November 29, 2018

Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis & other select endemic fungal infections (NIH)

Funding Opportunity Announcement (FOA) Numbers: PA-19-082

(R01 Clinical Trial Not Allowed)

Funding Opportunity Announcement (FOA) Numbers: PA-19-083

(R21 Clinical Trial Not Allowed)

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement is to support research activities that will contribute to the overall understanding of coccidioidomycosis, commonly known as Valley Fever, and other select endemic fungal diseases including histoplasmosis and blastomycosis.  This research opportunity encourages studies that address diverse scientific areas such as: 1) pathogenesis; 2) host response; 3) disease transmission; 4) natural history and environmental factors contributing to disease; 5) vaccines; 6) diagnostics; and 7) therapeutics; with the ultimate goal of advancing the field towards solutions for the improved detection, prevention and treatment of select endemic mycoses.

Specific areas of research interest

Specific areas of research interest are focused on coccidioidomycosis, histoplasmosis and blastomycosis and include, but are not limited to: 

Improve understanding of biology, transmission and pathogenesis of infection:
  • Improve understanding of pathogenesis
  • Expand understanding of the pathogen life cycle, including the role of climate and geography, host factors, physical and environmental factors that contribute to disease
  • Improve genotypic and phenotypic characterization associated with adverse clinical outcomes, and host immunity
  • Expand understanding of speciation and impact on clinical outcome
Identify/characterize host responses required for protection:
  • Determine the interaction of innate and adaptive immunity in response to infection
  • Identify immune markers associated with reduced disease severity
  • Elucidate mechanisms of protective immunity vs. those that ameliorate symptomatic disease
Support rational design of Coccidioides and other select endemic fungal pathogen vaccines:
  • Identify immunogens that elicit broad protection
  • Advance new vaccine approaches into preclinical models that exploit emerging antigen design strategies, novel technologies, and/or platforms
  • Define mechanisms and correlates of vaccine-induced protection
  • Test adjuvants and alternative delivery methods to enhance breadth and durability of immunity   
  • Develop novel therapeutics to clear infection
  • Identify biomarkers that could inform disease progression and contribute to rapid diagnostics
*This FOA will not support projects focused on HIV/AIDS.

Eligibility

Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions.

Award Budget

PA-19-082

Application budgets are not limited but need to reflect the actual needs of the proposed project.

PA-19-083

Direct costs are limited to $275,000 over a two-year project period, with no more than $200,000 in direct costs allowed in any single year.

Award Project Period

PA-19-082
The maximum project period is 5 years.

PA-19-083
The maximum project period is two years.   

Key Dates

PA-19-082
Open Date (Earliest Submission Date): January 05, 2019

PA-19-083
Open Date (Earliest Submission Date): January 16, 2019

Letter of Intent Due Date(s): N/A

*Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date: January 8, 2022

Deadline
Application Due Date(s)

PA-19-082
The first standard application due date for this FOA is February 05, 2019.
Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

PA-19-083
The first standard application due date for this FOA is February 16, 2019.
Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Posted by at
Subscribe to: Posts (Atom)